Tag: Viking Therapeutics

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsViking Therapeutics

Volta Finance Limited – Director/PDMR Shareholding

H-FARM International Schools officially join Nord Anglia Education following regulatory approvals

BMO Asset Management Inc. Announces Unit Splits, Enhancing Accessibility to BMO Asset Allocation Exchange Traded Funds

Tag: Viking Therapeutics

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us